{"id":179989,"date":"2026-02-09T03:44:48","date_gmt":"2026-02-09T08:44:48","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=179989"},"modified":"2026-02-09T03:44:48","modified_gmt":"2026-02-09T08:44:48","slug":"healthcare-global-enterprises-limited-reports-13-revenue-growth-in-third-quarter-fy26","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/healthcare-global-enterprises-limited-reports-13-revenue-growth-in-third-quarter-fy26\/","title":{"rendered":"Healthcare Global Enterprises Limited Reports 13% Revenue Growth in Third Quarter FY26"},"content":{"rendered":"\n<p><strong>HealthCare Global Enterprises Limited (NSE: HCG; BSE: 539787)<\/strong> India\u2019s largest specialized cancer care provider, reported 13% revenue growth and 20% adjusted EBITDA expansion for the third quarter ended December 31, 2025. On the reporting day, the stock price reached \u20b9564.20, a 0.78% decrease, implying a capitalization of \u20b97,955.65 crore.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Quarterly Results<\/strong><\/h2>\n\n\n\n<p>Total revenue reached \u20b96,331 million for the quarter, compared to \u20b95,586 million year-ago. Adjusted EBITDA grew 20% to \u20b91,108 million, resulting in a margin expansion of 98 basis points to 17.5%. The Board of Directors approved these unaudited standalone and consolidated financial results for the quarter. Adjusted profit after tax was \u20b96 million, a decline from \u20b970 million year-over-year.<\/p>\n\n\n\n<p>This decline was attributed to higher depreciation and interest costs totaling \u20b91,055 million related to growth investments. A reported loss of \u20b994 million included a \u20b9127 million exceptional charge for new Labor code impacts. Excluding fertility services, volume grew 8% while Average Revenue Per Occupied Bed (ARPP) increased 5%.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Annual Performance Context<\/strong><\/h2>\n\n\n\n<p>In the first nine months of fiscal year 2026, revenue totaled \u20b918,931 million, a 16% increase. Adjusted EBITDA rose 20% to \u20b93,458 million, with margins at 18.3%. Nine-month adjusted profit after tax was \u20b9216 million compared to \u20b9371 million previously. Pre-tax return on capital employed was 13.3%. Payor mix consisted of 55% from cash and insurance and 33% from government schemes. Medical oncology represented 38% of total revenue.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Business and Operations Update<\/strong><\/h2>\n\n\n\n<p>The West cluster accounted for 45% of revenue and grew 17% on patient inflows in Gujarat and Maharashtra. South cluster revenue increased 9% to account for 39% of the total, despite disruptions to state-sponsored schemes in Andhra Pradesh. East cluster revenue rose 12% on penetration in Ranchi and Cuttack. Kenya operations reported 42% year-over-year growth to \u20b9157 million, while Milann fertility revenue increased 11%. Total capital expenditure was \u20b92,227 million. Net debt, including capital leases, stood at \u20b916,337 million.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/Earnings-Snapshot-6-1024x572.png\" alt=\"\" class=\"wp-image-179990\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/Earnings-Snapshot-6-1024x572.png 1024w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/Earnings-Snapshot-6-300x167.png 300w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/Earnings-Snapshot-6-768x429.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/Earnings-Snapshot-6-1536x857.png 1536w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/Earnings-Snapshot-6-2048x1143.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Forward Outlook<\/strong><\/h2>\n\n\n\n<p>The 120-bed North Bangalore Greenfield Hospital is scheduled to operationalize by the end of the fourth quarter of fiscal year 2026. This facility will introduce MR-LINAC technology to the region. Strategic priorities include brownfield expansions and developing asset-light adjacencies. The company has completed leadership recruitment across marketing and international business. New leaders for finance, technology, clinical strategy, and investor relations roles join by fiscal year 2027. No specific financial guidance was provided.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Performance Summary<\/strong><\/h2>\n\n\n\n<p>Revenue and operating profit increased across all geographic clusters during the third quarter. Operating margins improved through leverage, although net profit was affected by exceptional items and growth-related costs. The company maintains a network of 25 hospitals and 38 LINACs. Network-wide growth was supported by simultaneous increases in patient volumes and average revenue per bed. Recent efforts focused on clinical technology differentiation and strengthening the management team.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HealthCare Global Enterprises Limited (NSE: HCG; BSE: 539787) India\u2019s largest specialized cancer care provider, reported 13% revenue growth and 20% adjusted EBITDA expansion for the third quarter ended December 31, 2025. On the reporting day, the stock price reached \u20b9564.20, a 0.78% decrease, implying a capitalization of \u20b97,955.65 crore. Quarterly Results Total revenue reached \u20b96,331 [&hellip;]<\/p>\n","protected":false},"author":2396,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,5747],"tags":[10169,15980,8157,15979],"class_list":["post-179989","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-healthcare-stocks","tag-earnings","tag-hcg","tag-healthcare","tag-healthcare-global-enterprises"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":178256,"url":"https:\/\/alphastreet.com\/india\/sagility-limited-shares-trade-lower-after-q3-fy26-results-revenue-up-35-7-yoy\/","url_meta":{"origin":179989,"position":0},"title":"Sagility Limited Shares Trade Lower After Q3 FY26 Results; Revenue Up 35.7% YoY","author":"Staff Correspondent","date":"January 28, 2026","format":false,"excerpt":"Sagility Limited (NSE: SAGILITY) shares slipped in early trade on Wednesday after the company reported a strong set of third-quarter fiscal 2026 results. The stock was last quoted around \u20b951.7, down modestly on the day, after recent strength from earlier earnings momentum. The share price remains within a 52-week range\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":178238,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-q3-fy26-revenue-rises-22-shares-steady-in-early-trade\/","url_meta":{"origin":179989,"position":1},"title":"Gland Pharma Limited Q3 FY26 Revenue Rises 22%, Shares Steady in Early Trade","author":"Staff Correspondent","date":"January 28, 2026","format":false,"excerpt":"Gland Pharma Limited (NSE: GLAND) shares were trading around \u20b91,688, up about 0.8% in early Wednesday deals, after the Hyderabad-based injectables maker reported its third-quarter results. The stock trades well below its 52-week high of \u20b92,131 and above its 52-week low near \u20b91,278, reflecting a sideways to slightly softer trend\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":180820,"url":"https:\/\/alphastreet.com\/india\/firstcry-posts-q3-fy26-revenue-rise-and-adjusted-ebitda-improvement-as-core-segment-returns-to-profit\/","url_meta":{"origin":179989,"position":2},"title":"FirstCry posts Q3 FY26 revenue rise and adjusted EBITDA improvement as core segment returns to profit","author":"Staff Correspondent","date":"February 13, 2026","format":false,"excerpt":"Business Overview Brainbees Solutions Limited (NSE: FIRSTCRY, BSE: 544226) operates a multi-channel platform for mothers, babies, and children, combining e-commerce, company-operated and franchise modern stores, a house-of-brands business (Globalbees), and education services. The group runs India's multi-channel operations alongside online platforms in the UAE and the Kingdom of Saudi Arabia\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":181183,"url":"https:\/\/alphastreet.com\/india\/narayana-hrudayalaya-revenue-surges-61-on-united-kingdom-expansion\/","url_meta":{"origin":179989,"position":3},"title":"Narayana Hrudayalaya Revenue Surges 61% on United Kingdom Expansion","author":"Staff Correspondent","date":"February 17, 2026","format":false,"excerpt":"Narayana Hrudayalaya Limited's (NSE: NH) consolidated revenue reached record levels following the strategic acquisition of healthcare operations in the United Kingdom. While operational performance remains strong across India and the Cayman Islands, one-time acquisition costs and labor code adjustments impacted quarterly net profit. the company reported a 61.2% year-over-year increase\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":180506,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-cohance-lifesciences-reports-q3-and-nine-month-revenue-and-profit-decline-amid-inventory-normalization\/","url_meta":{"origin":179989,"position":4},"title":"Earnings Summary &#8211; Cohance Lifesciences Reports Q3 and Nine-Month Revenue and Profit Decline Amid Inventory Normalization","author":"Staff Correspondent","date":"February 12, 2026","format":false,"excerpt":"Cohance Lifesciences Limited (NSE: COHANCE) is a global contract research, development, and manufacturing organization focused on innovator partnerships. The company reported a 19.5% year-on-year decline in consolidated revenue for the quarter ended December 31, 2025, as inventory de-stocking and timing shifts impacted commercial drawdowns. Shares of Cohance traded lower on\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177629,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-reports-q3-fy26-revenue-of-%e2%82%b92-9-billion-ebitda-declines-amid-approval-delays\/","url_meta":{"origin":179989,"position":5},"title":"OneSource Specialty Pharma Ltd reports Q3 FY26 revenue of \u20b92.9 billion, EBITDA declines amid approval delays","author":"Staff Correspondent","date":"January 24, 2026","format":false,"excerpt":"OneSource Specialty Pharma Ltd (BSE: 544292 \/ NSE: ONESOURCE) reported consolidated revenue of \u20b92.9 billion for the quarter ended December 31, 2025, a decline of 26% year-on-year, according to its Q3 FY26 earnings release. EBITDA stood at \u20b9173 million, down 88% from the corresponding quarter last year, while adjusted profit\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2396"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179989"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179989\/revisions"}],"predecessor-version":[{"id":179991,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179989\/revisions\/179991"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}